CT-P27 / Celltrion - LARVOL DELTA

Impact of early versus delayed intrapleural fibrinolytics on pleural infection outcomes: an observational study (BTS WM 2025) - "All received drainage ± fibrinolytics (Alteplase 10 mg + DNase 5 mg daily for up to 3 days). View this table: View inline View popup Download powerpoint Abstract P271 Table 1 Conclusions Early fibrinolytic therapy appears to reduce hospital stay and chest tube duration without increasing mortality or requirement for surgery. Further research is needed."

Clinical • Observational data • Infectious Disease

Do self-drainers have higher indwelling pleural catheter infection rates than non-self-drainers? (BTS WM 2025) - "Based on this, our service is introducing a structured checklist and competency-based 'license' for all patients and carers undertaking self-management. These tools are designed to serve both as a practical aide-mémoire and as a framework for assessing aseptic technique in self-management."

Breast Cancer • Hematological Malignancies • Infectious Disease • Lymphoma • Mesothelioma • Respiratory Diseases • Solid Tumor

A novel ambulatory pleural effusion pathway in a tertiary referral hospital in ireland reduced pleural effusion admissions by 31% over 9 months (BTS WM 2025) - "Based on this, our pilot pathway reduced admissions involving pleural effusion procedures by 31% (i.e. 55/177), saving 894 bed days over 9 months. Download figure Open in new tab Download powerpoint Abstract P273 Figure 1 Conclusion A pilot Ambulatory Pleural Effusion Pathway can substantially reduce admissions to an Irish hospital for pleural effusion procedures and save bed days."

Clinical • Pleural effusion • Respiratory Diseases

Evaluating age-adjusted D-dimer cut-offs and the role of higher multipliers in pulmonary embolism diagnosis (BTS WM 2025) - "Adoption of AADD with a ×11 multiplier could enhance cost-effectiveness and patient safety, particularly in older populations vulnerable to contrast-related complications. Further multicentre studies are warranted to validate these findings."

Cardiovascular • Mood Disorders • Pulmonary Embolism • Respiratory Diseases

Unexpected activity of the pleural nurse specialist for IPC patients in a tertiary centre (BTS WM 2025) - "The capacity of the PNS to triage concerns, arrange timely intervention, and support patients holistically suggests a model of care that is both patient-centred and resource-efficient. Further work is needed to evaluate the impact of non-IPC-related PNS contacts on broader service delivery."

Clinical • Palliative care • Respiratory Diseases

Can antifibrotic side-effect decision aids improve patient tolerance and continuation of antifibrotic medication? (BTS WM 2025) - "There was no increase in patient contacts outside the established antifibrotic pathway, with a higher proportion of patients not utilising the contact line within the first 3 months (p=0.004). View this table: View inline View popup Download powerpoint Abstract P27 Table 1 Discussion The Decision Aids have had a positive impact on patient tolerance and treatment continuation during the initial 3-month period without a significant increase in patient contacts to the specialist nurse contact line."

Adverse events • Clinical • Idiopathic Pulmonary Fibrosis • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Diagnostic utility and cost effectiveness of pleural fluid analysis during local anaesthetic thoracoscopy (BTS WM 2025) - "Routine use of these tests add healthcare costs without any benefit. Microbiological analysis, however, could be considered in clinically relevant cases where infection is suspected."

Cost effectiveness • HEOR • Anesthesia • Infectious Disease • Respiratory Diseases

In Vitro Induction of Dormancy in Multiple Myeloma to Study Tumor Cell Reactivation and Relapse (DGHO 2025) - "We established in vitro methods for inducing dormancy in multiple myeloma cells, providing a foundation for studying this state using 3 different in vitro approaches. This work may ultimately contribute to the development of therapeutic strategies targeting dormant cells to prevent relapse."

Preclinical • Tumor cell • Hematological Malignancies • Multiple Myeloma • Oncology

Early infliximab use is associated with less disease progression in luminal crohn's disease: a real-world tertiary centre experience (BSG 2025) - "However, in patients with luminal inflammatory CD who started therapy within 2 years of disease onset there was less disease progression, defined as extension in location, behaviour or new perianal disease (2/52 vs 10/65 chi sq 4.18 p=0.04) and a trend towards less systemic steroid use (4/52 vs 13/65 chi sq 3.53 p=0.06).Download figure Open in new tab Download powerpoint Abstract P275 Figure 1 Persistence on therapy, surgery and hospitalisation free survival, categorised by duration from diagnosis until first infliximab dose*luminal = Montreal B1P0Conclusions Early infliximab therapy is associated with less disease progression and less use of systemic steroids. The lack of variation in other outcomes may be due to historical case selection for advanced therapies."

Clinical • Real-world • Real-world evidence • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

The case of the vanishing CAN (colitis-associated neoplasia) (BSG 2025) - "She was intolerant to mesalazine/azathioprine and initially reluctant to start Infliximab.Surveillance in May 2023 showed a 20mm flat polyp in the splenic flexure (SF)...There was variable loss of MLH1 and null pattern of P53, which further confirmed the diagnosis.Download figure Open in new tab Download powerpoint Abstract P276 Figure 1 Conclusions We present a case of a young patient with clinically indolent IBD and concomitant PSC who benefitted by 'aggressive' medical treatment, as this allowed accurate dysplasia assessment. More importantly, this case demonstrates a challenging histological diagnosis of predominantly non-conventional IBD dysplasia, both visible and invisible, which was initially 'missed' in the resection specimen, despite the biopsy diagnosis of subtle, yet classical, dysplasia features. Pathologists need to be aware of these cytoarchitectural and immunohistochemical features to avoid misdiagnosis and disservice to patients and..."

Clinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Oncology • Ulcerative Colitis • MLH1 • SATB2

Vedolizumab in UC: long-term, real-world treatment persistence, mucosal healing and corticosteroid-free clinical remission (BSG 2025) - "Corticosteroid-free CR rates at 1 and 2 years were 42.7% (95% CI 38.4–47.1; 22 studies) and 43.4% (95% CI 27.9–60.2; 5 studies); higher rates were observed in biologic-naive vs experienced patients at 1 year.Conclusions This MA of real-world VDZ studies showed high rates of long-term persistence, MH, and corticosteroid-free CR. MH rates may not have been systematically assessed across studies.View this table:View inline View popup Abstract P27 Table 1"

Clinical • HEOR • Real-world • Real-world evidence • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Comparative analysis of a simple POPSIL score with lemman index to define the burden of organ damage in crohn's disease (BSG 2025) - "Its ease of calculation suggests that it may be a more practical method to assess burden of organ damage over time, response to drug therapy and prognostic determination of disease course. To develop the POPSIL score, we will incorporate patient-reported outcomes and larger scale validation of this approach."

Crohn's disease • Fatigue • Gastroenterology • Immunology • Inflammation • Inflammatory Bowel Disease • Pain

Real world experience from a tertiary centre in treatment with risankizumab after ustekinumab treatment failure in patients with crohn's disease (BSG 2025) - "For the reminder of patients, it was too early to determine if they had responded to risankizumab. The duration of treatment with risankizumab was comparable between the two groups (average of 255 days for prior escalated ustekinumab dosing and 221 days for those on standard dosing).Download figure Open in new tab Download powerpoint Abstract P270 Figure 1 Conclusion In this single centre cohort of medically refractory patients with Crohn's disease, there was a benefit in switching from both standard and dose escalated ustekinumab to standard dose risankizumab, with over half of patients achieving clinical, radiological or endoscopic response or remission."

Clinical • Real-world • Real-world evidence • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • IL12A • IL23A

A Study to Evaluate the Efficacy and Safety of CT-P27 in Acute Uncomplicated Influenza A Infection (clinicaltrials.gov) - P2b | N=228 | Terminated | Sponsor: Celltrion | Unknown status ➔ Terminated; CT-P27 2.2 is inactivated

Trial termination • Infectious Disease • Influenza • Respiratory Diseases

Specific Conformational Dynamics and Expansion Underpin a Multi-Step Mechanism for Specific Binding of p27 with Cdk2/Cyclin A. (PubMed, J Mol Biol) - "In summary, the binding interaction involves three steps: i) D1 initiates binding, ii) p27 wraps around Cdk2/Cyclin A and D2 binds, and iii) the fully-formed fuzzy ternary complex is formed concomitantly with extension of the post-KID region. An understanding of how the IDP nature of p27 underpins its functional interactions with Cdk2/Cyclin A provides insight into the complex binding mechanisms of IDPs and their regulatory mechanisms."

Journal

Broader neutralization of CT-P27 against influenza A subtypes by combining two human monoclonal antibodies. (PubMed, PLoS One) - "Moreover, CT-P27 showed in vivo therapeutic efficacy, long prophylactic potency, and synergistic effect with oseltamivir in influenza virus-challenged mouse models. Our findings provide a novel therapeutic opportunity for more efficient treatment of influenza."

Journal • Infectious Disease

Celltrion announces positive pre-clinical results for COVID- 19 antiviral antibody treatment, showing improvement in recovery time (Streetinsider.com) - "Celltrion is drawing on its expertise, innovation and previous experience in coronaviruses, such as efforts researching the efficacy of CT-P38, an investigational antibody to treat Middle East Respiratory Syndrome (MERS), as well as CT-P27, a multi-antibody drug for influenza which is being tested in a phase 2b study, to develop a safe and effective treatment for COVID-19..."

Clinical • Infectious Disease

A Study to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model (clinicaltrials.gov) - P2a; N=81; Completed; Sponsor: Celltrion; Active, not recruiting ➔ Completed

Clinical • Trial completion

The intronic long noncoding RNA iLnc-p27 regulates p27 protein expression and cellular quiescence (LCC 2020) - "In contrast, overexpression of iLnc-p27 promoted induction of p27highKi67low quiescent cells. Collectively, these results have identified the intronic lncRNA iLnc-p27 as an important regulator of cellular quiescence through facilitating p27 protein expression."

CDKN1B

Contalactone, a contaminant formed during chemical synthesis of the strigolactone reference GR24 is also a strigolactone mimic. (PubMed, Phytochemistry) - "Quality of GR24 samples can be easily checked by carrying out microscale hydrolysis in a basic aqueous medium to easily detect P270 as indicator of the presence of the contalactone impurity. In all cases, before being used for bioassays, GR24 must be careful purified by preparative HPLC."

Journal